RenovoRx, Inc. (RNXT) News
Filter RNXT News Items
RNXT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RNXT News Highlights
- For RNXT, its 30 day story count is now at 3.
- Over the past 8 days, the trend for RNXT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG, III and PCT are the most mentioned tickers in articles about RNXT.
Latest RNXT News From Around the Web
Below are the latest news stories about RENOVORX INC that investors may wish to consider to help them evaluate RNXT as an investment opportunity.
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct CancerLOS ALTOS, Calif., December 21, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the expansion of their clinical development pipeline in preparation for the commencement of a second Phase III trial. The CouGar Trial will evaluate RenovoGem in bile duct cancer, specifically unresectable locally advanced extrahepatic cholangiocarcinoma |
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific MeetingLOS ALTOS, Calif., December 19, 2023--RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the acceptance of a clinical data abstract for the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-28 in Salt Lake City, Utah. The abstract will highlight the Company’s lead product candidate, RenovoGem, and proprietary Trans-Arterial Micro-Perf |
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy PlatformLOS ALTOS, Calif., December 13, 2023--RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the Company has filed an international patent application under the Patent Cooperation Treaty (PCT) for its novel Trans-Arterial Micro-Perfusion (TAMP) therapy platform. The Company already holds a strong intellectual property portfolio with 9 issued patents and 9 pending patents |
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.LOS ALTOS, Calif., November 16, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of E |
RenovoRx Reports Third Quarter 2023 Financial Results and Operational HighlightsLOS ALTOS, Calif., November 14, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023. |
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023LOS ALTOS, Calif., October 02, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that CEO, Shaun Bagai, will present at the ROTH MKM Healthcare Opportunities Conference in New York on October 12, 2023. Register here. |
RenovoRx Reports Second Quarter 2023 Financial Results and Operational HighlightsLOS ALTOS, Calif., August 17, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the second quarter ended June 30, 2023. |
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth ConferenceLOS ALTOS, Calif., July 31, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA. Register here to access the live webcast. |
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) PlatformLOS ALTOS, Calif. & SYDNEY, July 20, 2023--RenovoRx, Inc. ("RenovoRx") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd ("Imugene") (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors. |
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic CancerLOS ALTOS, Calif., June 29, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today presented new positive data on progression-free survival (PFS) from the pivotal Phase III open label TIGeR-PaC study of RenovoGem (intra-arterial administration of gemcitabine) in locally advanced pancreatic cancer (LAPC). The interim data was featured as a late-breaking oral presentation at the 2023 ESMO World |